Mylan

Mylan

Mylan traces its origins to 1961 in White Sulphur Springs, West Virginia, where it began as a struggling distributor before pivoting to generic drug manufacturing. The company relocated to Canonsburg, Pennsylvania, and under the leadership of Executive Chairman Robert J. Coury and CEO Heather Bresch, transformed into a global generics powerhouse. Bresch, the daughter of US Senator Joe Manchin, joined the company in 1992 and rose through the ranks amid scrutiny of her MBA credentials, which the University of Southern California later retroactively awarded following a board-level inquiry. Despite the controversy, she drove an aggressive international expansion strategy that redefined the company's footprint. The company's strategy centered on acquiring difficult-to-manufacture generics and building a massive global distribution network. Mylan operates across the full pharmaceutical value chain, from active pharmaceutical ingredient (API) production through finished dosage forms, covering therapeutic areas including respiratory, antiretroviral, and central nervous system disorders. The 2007 acquisition of the generics arm of Merck KGaA and the 2013 purchase of Agila Specialties from Strides Arcolab expanded its injectables capability dramatically. The 2015 hostile pursuit of Perrigo—which ultimately failed—revealed a disciplined but aggressive capital allocation philosophy. Their most scrutinized asset, EpiPen, became the center of Congressional hearings in 2016 when the price for a two-pack rose from roughly $100 in 2007 to over $600, putting the company's pricing model under intense public and political pressure. Mylan employed approximately 35,000 people globally before its combination with Upjohn, with facilities spanning the United States, Ireland, India, Japan, and the Netherlands. The company long maintained a tax inversion structure, reorganizing under a Dutch parent company in 2015, though executive management remained in Canonsburg. In July 2019, Mylan announced a definitive agreement to combine with Pfizer's off-patent branded and generic established medicines business, Upjohn, in an all-stock Reverse Morris Trust transaction. The deal closed in November 2020, forming Viatris, with Mylan's Bresch retiring at close and the combined entity headquartered in Canonsburg. This merger fundamentally altered the corporate structure, absorbing Mylan into a significantly larger, publicly traded pharmaceutical entity. Mylan's structural differentiator lay in its self-identification as a pharmaceutical manufacturing company rather than a mere marketer. Unlike many generic competitors who outsource API production, Mylan vertically integrated backward, operating one of the world's largest active pharmaceutical ingredient manufacturing networks. This architecture allowed the company to launch so-called "authorized generics" during legal challenges to its own branded products, creating a peculiar competitive moat where it could compete against itself while blocking third-party generic entrants. The governance model, long dominated by Coury and Bresch, faced persistent criticism from activist investors, but their control enabled the long-duration capital allocation decisions required for the Upjohn merger.